BioCentury
ARTICLE | Clinical News

APG101: Phase I/II started

October 3, 2016 7:00 AM UTC

Canbridge began a Taiwanese Phase I/II trial to evaluate once-weekly 200 and 400 mg IV CAN-008 plus temozolomide in about 55 patients with newly diagnosed GBM. The trial comprises an open-label, dose-...